Landos Biopharma Past Earnings Performance
Past criteria checks 0/6
Landos Biopharma's earnings have been declining at an average annual rate of -8.5%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-8.5%
Earnings growth rate
25.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -100.0% |
| Return on equity | -107.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
Mar 22
Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer
Sep 06Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky
Aug 19Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
May 05Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business
Nov 17Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting
Jun 14Landos Biopharma (LABP) Investor Presentation - Slideshow
Jun 08We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully
May 04Revenue & Expenses Breakdown
How Landos Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -25 | 14 | 12 |
| 31 Dec 23 | 0 | -22 | 11 | 12 |
| 30 Sep 23 | 0 | -21 | 11 | 13 |
| 30 Jun 23 | 0 | -23 | 11 | 14 |
| 31 Mar 23 | 0 | -30 | 14 | 18 |
| 31 Dec 22 | 0 | -39 | 15 | 26 |
| 30 Sep 22 | 0 | -54 | 18 | 36 |
| 30 Jun 22 | 0 | -59 | 19 | 40 |
| 31 Mar 22 | 18 | -43 | 16 | 45 |
| 31 Dec 21 | 18 | -38 | 15 | 42 |
| 30 Sep 21 | 18 | -30 | 10 | 38 |
| 30 Jun 21 | 18 | -25 | 8 | 36 |
| 31 Mar 21 | 0 | -34 | 7 | 28 |
| 31 Dec 20 | 0 | -30 | 5 | 25 |
| 30 Sep 20 | 0 | -22 | 4 | 19 |
| 30 Jun 20 | 0 | -17 | 3 | 14 |
| 31 Mar 20 | 0 | -16 | 2 | 14 |
| 31 Dec 19 | 0 | -13 | 1 | 12 |
Quality Earnings: LABP is currently unprofitable.
Growing Profit Margin: LABP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LABP is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare LABP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LABP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: LABP has a negative Return on Equity (-107.1%), as it is currently unprofitable.